Amendments to the Abstract of the Disclosure

Please insert the following Abstract on a separate sheet (attached) as page 21a in the application:

The present invention relates to a stable liquid preparation comprising a camptothecin derivative which is prepared by binding a compound of the formula [I]:

wherein R¹ is a substituted or unsubstituted lower alkyl group, X¹ is a group of the formula:

-NHR₂ (R₂ is a hydrogen atom or a lower alkyl group) or a hydroxy group and Alk is a straight or branched chain alkylene group optionally interrupted by an oxygen atom, and a polysaccharide having carboxyl groups via an amino acid or a peptide, or a pharmaceutically acceptable sat thereof, which is adjusted to pH 5-8, or a stable pharmaceutical composition produced by lyophilizing said liquid preparation.

2

RCS/njp